Efficacy and safety of rapid dose escalation of methotrexate in rheumatoid arthritis. Results of the multicenter “METEOR” study
Authors:
- V. N. AmirjanovaVAV. N. Amirjanova
- E. Yu. PolishchukEPE. Yu. Polishchuk
- O. N. AnoshenkovaOAO. N. Anoshenkova
- I. B. VinogradovaIVI. B. Vinogradova
- E. V. ZonovaEZE. V. Zonova
- L. V. IvanovaLIL. V. Ivanova
- R. R. SamigullinaRSR. R. Samigullina
- Т. С. СальниковаТСТ. С. Сальникова
- E. L. ShakhramanovaESE. L. Shakhramanova
- E. I. ShmidtESE. I. Shmidt
- S. P. YakupovaSYS. P. Yakupova
- A. M. LilaALA. M. Lila
Open Access
- 2 March 2025
- journal article
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (1) , 55-63
Abstract
The aim of the study – to analyze the effectiveness and tolerability of subcutaneous methotrexate (sc MTX) (Metorthrit; S.C. Rompharm Company S.R.L) in patients with rheumatoid arthritis (RA) with high disease activity and rapid dose escalation, to assess their quality of life (QoL) in real clinical practice.Material and methods. The study included 105 patients, mostly women, with a reliable diagnosis of RA with high disease activity (DAS-28 (Disease Activity Score 28) ≥5.1) aged 18 years and older and ineffectiveness of previous oral MTX therapy for at least 6 months or who had not received MTX. Sc MTX therapy was started at a dose of 15 mg/weekly. During the first month of therapy, a rapid escalation of the sc MTX dose of 2.5 mg/week was performed once a week. until the dose of 22.5 mg/week was reached, then, with insufficient response, the dose of sc MTX could be increased to 25 mg/week. The evaluation of the effectiveness of therapy, functional status, and QoL was carried out after 4–12–18–24 weeks.Results. After a rapid escalation of the sc MTX dose during the first month of the study, at all stages of follow-up, a rapid decrease in disease activity was noted for all standard indices (DAS-28 – from 5.8±0.75 to 2.93±1.05; CDAI (Clinical Disease Activity Score) – from 30.13±8.33 to 7.08±6.07; SDAI (Simplified Disease Activity Score) – from 32.78±9.64 to 7.48±6.53) and the activity index, which was evaluated by the patients themselves (RAPID-3 (Routine Assessment of Patient Index Data 3) from 16.18±4.6 to 5.56±4.66; p≤0.05). The number of patients with high disease activity according to DAS-28 decreased by 2 times by the week 4 of therapy (to 46.2%), after 12 weeks they remained 13.3%, and by week 24 high activity remained only in 4.4% of patients. There was a marked decrease in pain from 65.6±13.07 to 20.5±17.1 mm in VAS (Visual Analogue Score) (ppppp0.05), however, the number of infections in patients receiving GC was significantly higher (9.5% and 0.0%, respectively; p=0.009). The need for nonsteroidal anti-inflammatory drugs (NSAIDs) at the beginning of the study was in 93.2% of patients on average 21.1 days per month, after 24 weeks, the need for NSAIDs was in 54.4% of patients on average 3.8 days per month. In general, the safety profile of MTX was acceptable.Conclusion. With high RA activity, the tactics of starting therapy with sc MTX at a dose of 15 mg per week and a rapid escalation of its dose of 2.5 mg weekly to 22.5–25 mg/week, allows achieving therapy goals by 3 months in 17.8% of patients, and by 6 months in 54.5%, to quickly improve the QoL, reduce the level of pain, reduce the dose of GC by 3 months of therapy or completely cancel them, reduce the need for NSAIDs by 7 times with an acceptable level of therapy safety.Keywords
This publication has 26 references indexed in Scilit:
- Oral Versus Subcutaneous Methotrexate in Immune-Mediated Inflammatory Disorders: an Update of the Current LiteratureCurrent Rheumatology Reports, 2023
- To treat or not to treat rheumatoid arthritis with glucocorticoids? A reheated debateAutoimmunity Reviews, 2023
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis & Rheumatology, 2021
- Diagnosis and Management of Rheumatoid ArthritisJAMA, 2018
- Meta‐Regression of a Dose‐Response Relationship of Methotrexate in Mono‐ and Combination Therapy in Disease‐Modifying Antirheumatic Drug–Naive Early Rheumatoid Arthritis PatientsArthritis Care & Research, 2016
- Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysisSeminars in Arthritis and Rheumatism, 2016
- Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of AdministrationAdvances in Therapy, 2016
- Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trialsSeminars in Arthritis and Rheumatism, 2015
- Methotrexate in Rheumatoid Arthritis: Optimizing Therapy Among Different Formulations. Current and Emerging ParadigmsClinical Therapeutics, 2014
- Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six‐month, multicenter, randomized, double‐blind, controlled, phase IV trialArthritis & Rheumatism, 2007